A strategy for distinguishing optimal cancer subtypes

International Journal of Cancer

Volumn 129, Issue 4, 2011, Pages 931-937

  Begg, Colin B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

double primary cancers; etiologic heterogeneity; tumor sub types

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; GESTAGEN; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CLASSIFICATION; CANCER GENETICS; CANCER RISK; HUMAN; MATHEMATICAL ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; TAXONOMY;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; META-ANALYSIS AS TOPIC; MODELS, THEORETICAL; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK ASSESSMENT;

EID: 79959745909     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25714     Document Type: Article

References (41)

1. Harris TJR, McCormick F,. The molecular pathology of cancer. Nat Rev Clin Oncol 2010; 7: 251-65.
2. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, et al,. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
3. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, Shah K, Socci ND, Weir BA, Ho A, Chiang DY, Reva B, et al,. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 2010; 42: 715-21.
4. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, et al,. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
5. Troester MA, Swift-Scanlan T,. Challenges in studying the etiology of breast cancer subtypes. Breast Cancer Res 2009; 11: 104.
6. Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB, Begg CB, Caporaso N, Chanock S, DeMichele A, Figg WD, Gospodarowicz MK, et al,. Cancer survivorship-genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 2006; 98: 15-25. (Pubitemid 43057089)
7. Kuligina E, Reiner A, Imyanitov EN, Begg CB,. Evaluating cancer epidemiologic risk factors using multiple primary malignancies. Epidemiology 2010; 21: 366-72.
8. Begg CB, Berwick M,. A note on the estimation of relative risks of rare genetic susceptibility markers. Cancer Epidemiol Biomarkers Prev 1997; 6: 99-103. (Pubitemid 27069202)
9. Imyanitov EN, Cornelisse CJ, Devilee P,. Searching for susceptibility alleles: emphasis on bilateral breast cancer. Int J Cancer 2007; 121: 921-3. (Pubitemid 47106227)
10. Peto J, Mack TM,. High constant incidence in twins and other relatives of women with breast cancer. Nat Genet 2000; 26: 411-4.
11. Arpino G, Weiss HL, Clark GM, Hilsenbeck SG, Osborne CK,. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol 2005; 23: 4687-94. (Pubitemid 46224071)
12. Bachleitner-Hofmann T, Pichler-Gebhard B, Rudas M, Gnant M, Taucher S, Kandioler D, Janschek E, Dubsky P, Roka S, Sporn E, Jakesz R,. Pattern of hormone receptor status of secondary contralateral breast cancers in patients receiving adjuvant tamoxifen. Clin Cancer Res 2002; 8: 3427-32. (Pubitemid 35340717)
13. Gong SJ, Rha SY, Jeung HC, Roh JK, Yang WI, Chung HC,. Bilateral breast cancer: differential diagnosis using histological and biological parameters. Jpn J Clin Oncol 2007; 37: 487-92. (Pubitemid 47335466)
14. Hahnel R, Twaddle E,. The relationship between estrogen receptors in primary and secondary breast carcinomas and in sequential primary breast carcinomas. Breast Cancer Res Treat 1985; 5: 155-63. (Pubitemid 15124774)
15. Holdaway IM, Mason BH, Bennett RC, Alexander AI, Hahnel R, Kiang DT,. Estrogen receptors in bilateral breast cancer. Cancer 1988; 62: 109-13.
16. Idvall I, Ringberg A, Anderson H, Akerman M, Fernö M,. Histopathological and cell biological characteristics of ductal carcinoma in situ (DCIS) of the breast-a comparison between the primary DCIS and subsequent ipsilateral and contralateral tumours. Breast 2005; 14: 290-7. (Pubitemid 41110190)
17. Kollias J, Pinder SE, Denley HE, Ellis IO, Wencyk P, Bell JA, Elston CW, Blamey RW,. Phenotypic similarities in bilateral breast cancer. Breast Cancer Res Treat 2004; 85: 255-61. (Pubitemid 38987260)
18. Stark A, Lu M, Mackowiak P, Linden M,. Concordance of the hormone receptors and correlation of HER-2/neu overexpression of the metachronous cancers of contralateral breasts. Breast J 2005; 11: 183-7. (Pubitemid 40664061)
19. Swain SM, Wilson JW, Mamounas EP, Bryant J, Wickerham DL, Fisher B, Paik S, Wolmark N,. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst 2004; 96: 516-23. (Pubitemid 38559575)
20. Weitzel JN, Robson M, Pasini B, Manoukian S, Stoppa-Lyonnet D, Lynch HT, McLennan J, Foulkes WD, Wagner T, Tung N, Ghadirian P, Olopade O, et al,. A comparison of bilateral breast cancers in BRCA carriers. Cancer Epidemiol Biomarkers Prev 2005; 14: 1534-8. (Pubitemid 40807358)
21. Brown M, Bauer K, Pare M,. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004. Breast Cancer Res Treat 2010; 120: 217-27.
22. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, et al,. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-47. (Pubitemid 34651353)
23. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, Behm FG, Raimondi SC, Relling MV, Patel A, Cheng C, Campana D, et al,. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1: 133-43. (Pubitemid 41039160)
24. Michiels S, Koscielny S, Hill C,. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 2005; 365: 488-92. (Pubitemid 40215731)
25. Begg CB, Zhang ZF,. Statistical analysis of molecular epidemiology studies employing case-series. Cancer Epidemiol Biomarkers Prev 1994; 3: 173-5.
26. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME,. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004; 13: 1558-68. (Pubitemid 39331875)
27. Chen WY, Colditz GA,. Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancer. Nat Clin Pract Oncol 2007; 4: 415-23. (Pubitemid 47039692)
28. Ma H, Bernstein L, Pike MC, Ursin G,. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiologic studies. Breast Cancer Res 2006; 8 (4): R43.
29. Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, Bojesen SE, Nordestgaard BG, Axelsson CK, Arias JI, Milne RL, Ribas G, et al,. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 2008; 4 (4): e1000054.
30. Garcia-Closas M, Chanock S,. Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res 2008; 14: 8000-9.
31. Reeves GK, Pirie K, Green J, Bull D, Beral V,. Reproductive factors and specific histological types of breast cancer: prospective study and meta-analysis. Br J Cancer 2009; 100: 538-44.
32. Kwan ML,., Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, Lee MM, Ambrosone CB, Caan BJ,. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 2009; 11: R31.
33. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Cartun R, et al,. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007; 16: 439-43. (Pubitemid 46548646)
34. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, et al,. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
35. Imyanitov EN, Suspitsin EN, Grigoriev MY, Togo AV, Kuligina ESh, Belogubova EV, Pozharisski KM, Turkevich EA, Rodriquez C, Cornelisse CJ, Hanson KP, Theillet C,. Concordance of allelic imbalance profiles in synchronous and metachronous bilateral breast carcinomas. Int J Cancer 2002; 100: 557-64. (Pubitemid 34816156)
36. Begg CB,. On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2002; 94: 1221-6. (Pubitemid 34993872)
37. Ha PK, Califano JA,. The molecular biology of mucosal field cancerization of the head and neck. Crit Rev Oral Bio Med 2003; 14: 363-9. (Pubitemid 44560790)
38. Hafner C, Knuechel R, Stoehr R, Hartmann A,. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int J Cancer 2002; 101: 1-6. (Pubitemid 34832989)
39. Orlow I, Tommasi DV, Bloom B, Ostrovnaya I, Cotignola J, Mujumdar U, Busam KJ, Jungbluth AA, Scolyer RA, Thompson JF, Armstrong BK, Berwick M, et al,. Evaluation of the clonal origin of multiple primary melanomas using molecular profiling. J Invest Dermatol 2009; 129: 1972-82.
40. Girard N, Ostrovnaya I, Lau C, Park B, Ladanyi M, Finley D, Deshpande C, Rusch V, Orlow I, Travis WD, Pao W, Begg CB,. Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. Clin Cancer Res 2009; 15: 5184-90.
41. Neugut AI, Meadows AT, Robinson E, eds. Multiple Primary Cancers. Philadelphia: Lippincott Williams & Wilkins, 1999.